Kanoria Chemicals & Industries Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
KANORICHEM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.7 pts less than Nifty Microcap 250, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Kanoria Chemicals reported its Q1 FY26 results with standalone revenue from operations rising sharply to Rs 18,658 lakhs from Rs 11,168 lakhs in Q1 FY25, a jump of about 67% year-on-year. On a consolidated basis, revenue grew around 18% to Rs 45,378 lakhs. However, the company slipped into a standalone loss of Rs 406 lakhs (vs a small profit of Rs 64 lakhs a year ago) after booking a Rs 1,064 lakh impairment on its investment in Swiss subsidiary APAG Holding AG. Consolidated loss narrowed to Rs 1,378 lakhs from Rs 2,293 lakhs in Q1 FY25. The Board also approved a plan to dilute its stake in APAG from 55% to about 14.3% in Phase 1 by bringing in a strategic investor, with full exit planned by FY30. Standalone operating profit before depreciation and finance costs (PBDITDA) margin expanded to roughly 9.8% from 5.3% a year ago, driven by the strong top-line growth.
Short-term: Negative — the company returned to a loss on the back of an impairment charge, even as core chemicals revenue surged. Medium-term: The planned APAG divestment will reduce exposure to the loss-making Electronics-Automotive segment and bring in fresh capital, but shareholders will see meaningful dilution in the Swiss subsidiary.